Hemofiltration methods for treatment of diseases in a mammal

• US 7,291,122 B2
• Filed: 05/12/2004
• Issued: 11/06/2007
• Est. Priority Date: 03/24/2000
• Status: Expired due to Fees

• Current Assignee: Immunocept Medical Products, LLC (LMF Acquisition Opportunities, Inc.)
• Original Assignee: Immunocept LLC
• Inventors: Matson, James R.
• Primary Examiner(s): KIM, SUN U
• Application Number:
  US10/843,933
• Publication Number:
  US 20050029193A1
• Time in Patent Office: 1,273 Days
• Field of Search: 210/195.1, 210/195.2, 210/252, 210/258, 210/294, 210/295, 210/416.1, 210/428, 210/433.1, 210/434, 210/645, 210/650, 210/651, 210/660, 210/661, 210/663, 210/669, 422/44, 422/261, 435/2, 435/85.2, 435/219, 435/226, 514/1, 514/2, 514/12, 514/21, 530/380, 530/381, 530/382, 530/383, 530/384, 604/4.01, 604/5.01, 604/5.04, 604/6.09, 604/6.11
• US Class Current: 604/6.09
• CPC Class Codes: A61M 1/342 Adding solutions to the blood, e.g. substitution solutions for preventing coagulation A61M1/3672
• CPC Class Codes: A61M 1/3437 downstream of the filter, e.g. post-dilution with filtrate
• CPC Class Codes: A61M 1/3441 Substitution rate control as a function of the ultrafiltration rate
• CPC Class Codes: A61M 1/3455 Substitution fluids
• CPC Class Codes: A61M 1/3468 using treated filtrate as substitution fluid
• CPC Class Codes: A61M 1/3472 with treatment of the filtrate
• CPC Class Codes: A61M 1/3486 Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents

Abstract

A hemofiltration system and method to treat an Inflammatory Mediator Related Disease in a mammal, including chronic and acute diseases, include a hemofilter and an adsorptive device. The hemofilter removes ultrafiltrate from a blood stream extracted from the mammal to create a filtered blood stream and an ultrafiltrate stream. The adsorptive device may include one or more adsorbent materials and may be used to adsorb inflammatory mediators from the ultrafiltrate stream received from the hemofilter to create a post adsorption ultrafiltrate stream. The post adsorption ultrafiltrate stream may be selectively combined with the filtered blood stream and together with the filtered blood stream may be returned to the mammal.

Claims

1. A method for treating a disease in a mammal comprising:

pumping blood from the mammal using a blood pump;

transferring the blood from the blood pump to a hemofilter;

removing an ultrafiltrate from the blood using the hemofilter to create a filtered blood stream and an ultrafiltrate stream;

transferring the ultrafiltrate stream from the hemofilter to an adsorptive device containing at least one fixed adsorbent material;

selectively removing an inflammatory mediator which causes Compensatory Anti-inflammatory Response Syndrome from the ultrafiltrate stream using the adsorbent material to create a post adsorption ultrafiltrate stream;

combining at least a portion of the post adsorption ultrafiltrate stream with the filtered blood stream and returning the combined post adsorption ultrafiltrate stream and the filtered blood stream to the mammal;

transferring a portion of the post adsorption ultrafiltrate stream which is not returned to the mammal to a waste reservoir; and

providing at least one therapeutic agent to the blood.

2. The method of claim 1 further comprising transferring the post adsorption ultrafiltrate stream from the adsorptive device using an ultrafiltrate pump.

3. The method of claim 1 further comprising:

transferring the post adsorption ultrafiltrate stream from the adsorptive device using a first ultrafiltrate pump; and

transferring any portion of the post adsorption ultrafiltrate stream which is not returned to the mammal to the waste reservoir using a second ultrafiltrate pump.

4. The method of claim 1 wherein the mammal has a disease selected from a group consisting of:

Lupus erythematosis, Hemolytic Uremic Syndrome, Bullous Pemphigoid, pemphigus vulgaris, sepsis, fibromyalgia, rheumatoid conditions, chronic neuromuscular diseases, multiple sclerosis, Guillain-Barre syndrome, cryobulinemic vasculitis, chronic inflammatory demyelinating polyneuropathy, macular degeneration, chronic neuromuscular and multifocal motor neuropathy, coagulation disorders, and any combination thereof.

5. A method for treating Compensatory Anti-inflammatory Response Syndrome in a mammal comprising:

performing hemofiltration on blood from the mammal using a hemofilter to generate an ultrafiltrate;

transferring the ultrafiltrate to an adsorptive device containing at least one fixed adsorbent material;

selectively removing an inflammatory mediator which causes Compensatory Anti-inflammatory Response Syndrome from the ultrafiltrate using the adsorbent material to create a post adsorption ultrafiltrate;

returning at least a portion of the post adsorption ultrafiltrate to the mammal; and

providing at least one therapeutic agent to the blood.

6. The method of claim 5, wherein the mammal has a disease selected from a group consisting of:

Lupus erythematosis, Hemolytic Uremic Syndrome, Bullous Pemphigoid, pemphigus vulgaris, sepsis, fibromyalgia, rheumatoid conditions, chronic neuromuscular diseases, multiple sclerosis, Guillain-Barre syndrome, cryobulinemic vasculitis, chronic inflammatory demyelinating polyneuropathy, macular degeneration, chronic neuromuscular and multifocal motor neuropathy, coagulation disorders, and any combination thereof.

7. The method of claim 5, wherein the therapeutic agent comprises a biological agent.

8. The method of claim 5, wherein the therapeutic agent comprises a pharmaceutical agent.

9. The method of claim 5, wherein the therapeutic agent further comprises protein C or a protein C derivative.

10. The method of claim 9, further comprising the protein C or protein C derivative selected from a group consisting of:

recombinant activated protein C, human protein C, proteolytic, amidolytic and esterolytic protein C, and any combination thereof.

11. The method of claim 9, further comprising the therapeutic agent selected from a group consisting of:

monoclonal antibodies, receptor antagonists, anti-tumor necrosis factor, interleukin 1 receptor antagonists, endotoxin antibodies, allopurinol, elastase inhibitors, prostaglandin inhibitors, and any combination thereof.

12. A method for treating Compensatory Anti-inflammatory Response Syndrome in a mammal comprising:

receiving blood from the mammal;

filtering the blood using a hemofilter to remove an inflammatory mediator from the blood; and

providing at least one biological therapeutic agent to the blood to reduce adverse inflammatory mediator effects associated with treating Compensatory Anti-inflammatory Response Syndrome.

13. A method for treating a disease in a mammal comprising:

pumping blood from the mammal using a blood pump;

transferring the blood from the blood pump to a hemofilter;

removing an ultrafiltrate from the blood using the hemofilter to create a filtered blood stream and an ultrafiltrate stream;

transferring the ultrafiltrate stream from the hemofilter to an adsorptive device containing at least one fixed adsorbent material;

selectively removing an inflammatory mediator which causes an Inflammatory Mediator Related Disease from the ultrafiltrate stream using the adsorbent material to create a post adsorption ultrafiltrate stream;

combining at least a portion of the post adsorption ultrafiltrate stream with the filtered blood stream and returning the combined post adsorption ultrafiltrate stream and the filtered blood stream to the mammal;

transferring a portion of the post adsorption ultrafiltrate stream which is not returned to the mammal to a waste reservoir; and

providing at least one therapeutic agent to the blood.

14. The method of claim 13 further comprising transferring the post adsorption ultrafiltrate stream from the adsorptive device using an ultrafiltrate pump.

15. The method of claim 13 further comprising:

transferring the post adsorption ultrafiltrate stream from the adsorptive device using a first ultrafiltrate pump; and

transferring any portion of the post adsorption ultrafiltrate stream which is not returned to the mammal to the waste reservoir using a second ultrafiltrate pump.

16. The method of claim 13, wherein the mammal has a disease selected from a group consisting of:

Lupus erythematosis, Hemolytic Uremic Syndrome, Bullous Pemphigoid, pemphigus vulgaris, sepsis, fibromyalgia, rheumatoid conditions, chronic neuromuscular diseases, multiple sclerosis, Guillain-Barre syndrome, cryobulinemic vasculitis, chronic inflammatory demyelinating polyneuropathy, macular degeneration, chronic neuromuscular and multifocal motor neuropathy, coagulation disorders, and any combination thereof.

17. The method of claim 13, wherein the therapeutic agent comprises a biological agent.

18. The method of claim 13, wherein the therapeutic agent comprises a pharmaceutical agent.

19. The method of claim 13, wherein the therapeutic agent further comprises protein C or a protein C derivative.

20. The method of claim 19, further comprising the protein C or protein C derivative selected from a group consisting of:

recombinant activated protein C, human protein C, proteolytic, amidolytic and esterolytic protein C, and any combination thereof.

21. The method of claim 13, further comprising the therapeutic agent selected from a group consisting of:

monoclonal antibodies, receptor antagonists, anti-tumor necrosis factor, interleukin 1 receptor antagonists, endotoxin antibodies, allopurinol, elastase inhibitors, prostaglandin inhibitors, and any combination thereof.